ONC — BeOne Medicines Ltd. catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

4 verified catalyst event(s) for BeOne Medicines Ltd. (ticker ONC). Each is linked to its official source. Verified as of 2026-06-22.

Next verified catalyst

2026-09-22 — A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy an · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-09-22 in 3mo ESTIMATED	READOUT A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Mono Phase 2 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent	ONC BeOne Medicines Ltd.	Sonrotoclax, Zanubrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-11 (month) in 4mo ESTIMATED	READOUT A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Comb Phase 1/2 · Relapsed/Refractory Multiple Myeloma	ONC BeOne Medicines Ltd.	Sonrotoclax, Dexamethasone, Carfilzomib,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-11 (month) in 4mo ESTIMATED	READOUT A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell M Phase 1/2 · B-cell Malignancy, Marginal Zone Lymphoma	ONC BeOne Medicines Ltd.	BGB-16673	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-11 (month) in 4mo ESTIMATED	READOUT A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutini Phase 2 · Chronic Lymphocytic Leukemia	ONC BeOne Medicines Ltd.	Sonrotoclax, Zanubrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change